Curing hepatitis C in liver transplant recipients is associated with changes in immunosuppressant use

Journal of Clinical and Translational Hepatology

Volumn 4, Issue 1, 2016, Pages 32-38

  Saab, Sammy ^a   Rheem, Justin ^b   Jimenez, Melissa ^a   Bau, Sherona ^a   Choi, Gina ^a   Durazo, Francisco ^a   El Kabany, Mohammed ^a   Han, Steven ^a   Farid, Alexander ^a   Jamal, Naadir ^a   Grotts, Jonathan ^a   Elashoff, David ^a   Busuttil, Ronald W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Direct acting agents; Hepatitis C; Immunosuppressant; Liver transplantation

Indexed keywords

EID: 85010254285     PISSN: 22250719     EISSN: 23108819     Source Type: Journal    
DOI: 10.14218/JCTH.2016.00001     Document Type: Article

References (41)

1. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693–699. doi: 10.1056/NEJM199603143341104.
2. Rubin A, Aguilera V, Berenguer M. Liver transplantation and hepatitis C. Clin Res Hepatol Gastroenterol 2011;35:805–812. doi: 10.1016/j.clinre.2011. 04.009.
3. Martin P, DiMartini A, Feng S, Brown R Jr, Fallon M. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology 2014;59:1144. doi: 10.1002/hep.26972.
4. Starzl TE, Koep LJ, Halgrimson CG, Hood J, Schroter GP, Porter KA, Weil R, 3rd. Fifteen years of clinical liver transplantation. Gastroenterology 1979;77: 375–388.
5. Starzl TE, Iwatsuki S, Van Thiel DH, Gartner JC, Zitelli BJ, Malatack JJ, et al. Evolution of liver transplantation. Hepatology 1982;2:614–636. doi: 10.1002/hep.1840020516.
6. Calne RY, Williams R. Orthotopic liver transplantation: The first 60 patients. Br Med J 1977;1:471–476. doi: 10.1136/bmj.1.6059.471.
7. Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Charlton MR. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK longterm follow-up study. Am J Transplant 2010;10:1420–1427. doi: 10.1111/j.1600-6143.2010.03126.x.
8. Textor SC, Taler SJ, Canzanello VJ, Schwartz L, Augustine JE. Posttransplan-tation hypertension related to calcineurin inhibitors. Liver Transpl 2000;6: 521–530. doi: 10.1053/jlts.2000.9737.
9. Laryea M, Watt KD, Molinari M, Walsh MJ, McAlister VC, Marotta PJ, et al. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpl 2007;13:1109–1114. doi: 10.1002/lt.21126.
10. Chen T, Jia H, Li J, Chen X, Zhou H, Tian H. New onset diabetes mellitus after liver transplantation and hepatitis C virus infection: meta-analysis of clinical studies. Transpl Int 2009;22:408–415. doi: 10.1111/j.1432-2277.2008. 00804.x.
11. Kuo HT, Sampaio MS, Ye X, Reddy P, Martin P, Bunnapradist S. Risk factors for new-onset diabetes mellitus in adult liver transplant recipients, an analysis of the Organ Procurement and Transplant Network/ United Network for Organ Sharing database. Transplantation 2010;89:1134–1140. doi: 10.1097/TP. 0b013e3181d2fec1.
12. Gonwa TA, Mai ML, Melton LB, Hays SR, Goldstein RM, Levy MF, Klintmalm GB. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation 2001;72:1934–1939. doi: 10.1097/00007890-200112270-00012.
13. Paramesh AS, Roayaie S, Doan Y, Schwartz ME, Emre S, Fishbein T, et al. Post-liver transplant acute renal failure: factors predicting development of end-stage renal disease. Clin Transplant 2004;18:94–99. doi: 10.1046/j. 1399-0012.2003.00132.x.
14. Berenguer M. Hot topic in hepatitis C virus research: the type of immunosup-pression does not matter. Liver Transpl 2011;17:S24–28. doi: 10.1002/lt. 22347.
15. Kim WR, Lake JR, Smith JM, Skeans MA, Schladt DP, Edwards EB, et al. OPTN/SRTR 2013 annual data report: liver. Am J Transplant 2015;15:1–28. doi: 10.1111/ajt.13197.
16. Ghobrial RM, Steadman R, Gornbein J, Lassman C, Holt CD, Chen P, et al. A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg 2001;234: 384–393. doi: 10.1097/00000658-200109000-00012.
17. Crespo G, Marino Z, Navasa M, Forns X. Viral hepatitis in liver transplanta-tion. Gastroenterology 2012;142:1373–1383. doi: 10.1053/j.gastro.2012. 02.011.
18. Berenguer M, Prieto M, Rayón JM, Mora J, Pastor M, Ortiz V, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000;32:852–858. doi: 10.1053/jhep. 2000.17924.
19. Berenguer M, Palau A, Aguilera V, Rayón JM, Juan FS, Prieto M. Clinical ben-efits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008;8:679–687. doi: 10.1111/j.1600-6143.2007.02126.x.
20. Carrión JA, Navasa M, García-Retortillo M, García-Pagan JC, Crespo G, Bruguera M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007;132:1746–1756. doi: 10.1053/j.gastro.2007.03.041.
21. Saab S, Kalmaz D, Gajjar NA, Hiatt J, Durazo F, Han S, et al. Outcomes of acute rejection after interferon therapy in liver transplant recipients. Liver Transpl 2004;10:859–867. doi: 10.1002/lt.20157.
22. Selzner N, Guindi M, Renner EL, Berenguer M. Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients. J Hepatol 2011;55:207–217. doi: 10.1016/j.jhep.2010. 11.012.
23. Levitsky J, Fiel MI, Norvell JP, Wang E, Watt KD, Curry MP, et al. Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. Gastroenterology 2012;142:1132–1139. doi: 10.1053/j.gastro.2012.01.030.
24. Saab S, Jimenez M, Bau S, Goo T, Zhao D, Durazo F, et al. Treating fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin: a matched analysis. Clin Transplant 2015;29:813–819. doi: 10.1111/ctr.12584.
25. Saab S, Greenberg A, Li E, Bau SN, Durazo F, El-Kabany M, et al. Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recip-ients. Liver Int 2015;35:2442–2447. doi: 10.1111/liv.12856.
26. Kwo PY, Mantry PS, Coakley E, Te HS, Vargas HE, Brown R Jr, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med 2014;371:2375–2382. doi: 10.1056/NEJMoa1408921.
27. Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS, et al. SOLAR-1 Investigators. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenter-ology 2015;149:649–659. doi: 10.1053/j.gastro.2015.05.010.
28. Moini M, Schilsky ML, Tichy EM. Review on immunosuppression in liver trans-plantation. World J Hepatol 2015;7:1355–1368. doi: 10.4254/wjh.v7.i10. 1355.
29. Lan X, Liu MG, Chen HX, Liu HM, Zeng W, Wei D, Chen P. Efficacy of immu-nosuppression monotherapy after liver transplantation: a meta-analysis. World J Gastroenterol 2014;20:12330–12340. doi: 10.3748/wjg.v20.i34. 12330.
30. Manzia TM, Angelico R, Ciano P, Mugweru J, Owusu K, Sforza D, et al. Impact of immunosuppression minimization and withdrawal in long-term hepatitis C virus liver transplant recipients. World J Gastroenterol 2014;20:12217– 12225. doi: 10.3748/wjg.v20.i34.12217.
31. Londoño MC, Rimola A, O’Grady J, Sanchez-Fueyo A. Immunosuppression minimization vs. complete drug withdrawal in liver transplantation. J Hepatol 2013;59:872–879. doi: 10.1016/j.jhep.2013.04.003.
32. Liu Z, Chen Y, Tao R, Xv J, Meng J, Yong X. Tacrolimus-based versus cyclospor-ine-based immunosuppression in hepatitis C virus-infected patients after liver transplantation: a meta-analysis and systematic review. PLoS One 2014;9: e107057. doi: 10.1371/journal.pone.0107057.
33. Badri P, Dutta S, Coakley E, Cohen D, Ding B, Podsadecki T, et al. Pharma-cokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. Am J Transplant 2015;15:1313–1322. doi: 10.1111/ajt.13111.
34. Reddy KR, Everson G, Flamm S., Denning J, Arterburn S, Brandt-Sarif T, et al. Ledipasvir/Sofosbuvir with Ribavirin for the Treatment of HCV in Patients with Post Transplant Recurrence: Preliminary Results of a Prospective, Multicenter Study. Hepatology 2014;60:200A.
35. Charlton M, Gane E, Manns MP, Brown RS Jr, Curry MP, Kwo PY, et al. Sofos-buvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2015;148:108–117. doi: 10.1053/j.gastro.2014.10.001.
36. Niwa T, Yamamoto S, Saito M, Shiraga T, Takagi A. Effect of cyclosporine and tacrolimus on cytochrome p450 activities in human liver microsomes. Yaku-gaku Zasshi 2007;127:209–216. doi: 10.1248/yakushi.127.209.
37. Bengsch B, Seigel B, Ruhl M, Timm J, Kuntz M, Blum HE, et al. Coexpression of PD-1, 2B4, CD160, and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation. PLoS Pathog 2010;6: e1000947. doi: 10.1371/journal.ppat.1000947.
38. Klenerman P, Thimme R. T cell responses in hepatitis C: the good, the bad and the unconventional. Gut 2012;61:1226–1234. doi: 10.1136/gutjnl-2011-300620.
39. Abdel-Hakeem MS, Bédard N, Badr G, Ostrowski M, Sékaly RP, Bruneau J, et al. Comparison of immune restoration in early vs. late alpha interferon therapy against hepatitis C virus. J Virol 2010;84:10429–10435. doi: 10. 1128/JVI.01094-10.
40. Badr G, Bédard N, Abdel-Hakeem MS, Trautmann L, Willems B, Villeneuve J-P, et al. Early interferon therapy for hepatitis C virus infection rescues polyfunctional, long-lived CD8+ memory T cells. J Virol 2008;82:10017– 10031. doi: 10.1128/JVI.01083-08.
41. Bohne F, Londoño MC, Benítez C, Miquel R, Martínez-Llordella M, Russo C, et al. HCV-induced immune responses influence the development of opera-tional tolerance after liver transplantation in humans. Sci Transl Med 2014;6: 242ra81. doi: 10.1126/scitranslmed.3008793.